journal article·2026-07Open access

Marburg Virus Glycoprotein Is a Remarkable Virulent Factor Linked to Hemorrhagic Pathology: Evidence from Multimodal Experimental Systems

Ting Yao, Hang Liu, Yanfeng Yao, Wei Deng, Jiawen Sun, Zhenyu Kang, Ashaq Ali, Chao Shan, Zhiming Yuan, Fei Deng, Hualin Wang, Yun‐Jia Ning

Advanced Science· Volume 13· Issue 39

Abstract

ABSTRACT Marburg virus (MARV) causes Marburg virus disease (MVD), a severe hemorrhagic fever associated with high morbidity and mortality. No specific antiviral therapies are currently approved for MVD, and viral pathogenesis, particularly the viral pathogenic factor(s) involved, remains poorly defined. Here, we demonstrated that MARV glycoprotein (GP) can induce rounding and detachment of adherent cells, likely by shielding and downregulating cell surface molecules, mainly via its mucin‐like domain (MLD), disrupting monolayer barrier function. In an ex vivo rat vascular model, GP expression caused significant endothelial cell damage and increased vascular permeability. In vivo, MARV GP increases vascular permeability and exacerbates inflammation and tissue injury in mouse muscle and liver transduction models, validating its pathogenic activity. Deletion of the MLD largely abolished these pathogenic effects, indicating its significant role in MARV GP pathogenicity. In addition, using the ex vivo vascular model, we demonstrated the infectivity and pathogenicity of the authentic Ebola virus in vessels and validated the utility of this model as a tool for intervention research against filovirus infection and GP pathogenicity. This study uncovered the remarkable role of MARV GP as a hemorrhage‐related pathogenic factor through multimodal analyses, which may help advance our understanding of viral pathogenesis and lay a foundation for future therapeutic strategies.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Viral Infections and Outbreaks Research · Viral Infections and Vectors · Disaster Response and Management

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Virology and Biosafety Wuhan Institute of Virology Chinese Academy of Sciences Wuhan China

National Virus Resource Center Wuhan Institute of Virology Chinese Academy of Sciences Wuhan China

University of Chinese Academy of Sciences Beijing China

State Key Laboratory of Virology and Center for Biosafety Mega‐Science Chinese Academy of Sciences Wuhan China

Center of Excellence in Science and Applied Technologies Islamabad Pakistan

Hubei Jiangxia Laboratory Wuhan China

Funding

National Key Research and Development Program of China · Youth Innovation Promotion Association of the Chinese Academy of Sciences

References (67)

Show source-provided references
1. 10.1016/S1473‐3099(05)70125‐010.1016/S1473‐3099(05)70125‐0 ↗
2. 10.1503/cmaj.05050510.1503/cmaj.050505 ↗
3. 10.1053/j.spid.2005.05.00110.1053/j.spid.2005.05.001 ↗
4. 10.1086/52055110.1086/520551 ↗
5. 10.1016/j.cll.2009.12.00110.1016/j.cll.2009.12.001 ↗
6. 10.1093/labmed/lmy04610.1093/labmed/lmy046 ↗
7. 10.3390/v410187810.3390/v4101878 ↗
8. 10.3390/v1312239410.3390/v13122394 ↗
9. 10.1371/journal.ppat.101080510.1371/journal.ppat.1010805 ↗
10. 10.1016/S0140‐6736(23)00169‐110.1016/S0140‐6736(23)00169‐1 ↗
11. 10.1016/j.tmaid.2023.10257110.1016/j.tmaid.2023.102571 ↗
12. 10.1016/j.nmni.2023.10112310.1016/j.nmni.2023.101123 ↗
13. 10.1016/S1473‐3099(23)00221‐910.1016/S1473‐3099(23)00221‐9 ↗
14. 10.1002/iid3.98010.1002/iid3.980 ↗
15. 10.1016/S0140‐6736(24)02194‐910.1016/S0140‐6736(24)02194‐9 ↗
16. 10.1093/infdis/jiad16110.1093/infdis/jiad161 ↗
17. 10.1016/s2666‐5247(22)00258‐010.1016/s2666‐5247(22)00258‐0 ↗
18. 10.3389/fmicb.2023.123907910.3389/fmicb.2023.1239079 ↗
19. 10.1097/JS9.000000000000016210.1097/JS9.0000000000000162 ↗
20. WHO.Pathogens prioritization: a scientific framework for epidemic and pandemic research preparedness https://www.who.int/publications/m/item/pathogens‐prioritization‐a‐scientific‐framework‐for‐epidemic‐and‐pandemic‐research‐preparedness(2024).
21. 10.1080/21505594.2022.205476010.1080/21505594.2022.2054760 ↗
22. 10.1016/j.ijid.2020.07.04210.1016/j.ijid.2020.07.042 ↗
23. 10.1016/j.cell.2024.07.01210.1016/j.cell.2024.07.012 ↗
24. 10.1055/s‐2007‐96902510.1055/s‐2007‐969025 ↗
25. 10.1182/blood‐2017‐06‐74267610.1182/blood‐2017‐06‐742676 ↗
26. 10.1093/infdis/jiv09510.1093/infdis/jiv095 ↗
27. 10.1146/annurev‐immunol‐051116‐05241510.1146/annurev‐immunol‐051116‐052415 ↗
28. 10.3389/fimmu.2019.0252510.3389/fimmu.2019.02525 ↗
29. 10.3390/v806017810.3390/v8060178 ↗
30. 10.1006/viro.1999.011010.1006/viro.1999.0110 ↗
31. 10.3390/v604165410.3390/v6041654 ↗
32. 10.1016/j.ymthe.2022.09.00910.1016/j.ymthe.2022.09.009 ↗
33. 10.1016/j.chom.2017.12.00310.1016/j.chom.2017.12.003 ↗
34. 10.1128/mBio.01674‐1810.1128/mBio.01674‐18 ↗
35. 10.3390/v1305091310.3390/v13050913 ↗
36. 10.1016/j.cell.2015.01.04110.1016/j.cell.2015.01.041 ↗
37. 10.1016/j.virusres.2004.08.01410.1016/j.virusres.2004.08.014 ↗
38. 10.1016/s0065‐3527(05)64011‐010.1016/s0065‐3527(05)64011‐0 ↗
39. 10.1007/s13238‐017‐0471‐x10.1007/s13238‐017‐0471‐x ↗
40. 10.1007/s12250‐016‐3850‐110.1007/s12250‐016‐3850‐1 ↗
41. 10.1016/j.virol.2008.10.02910.1016/j.virol.2008.10.029 ↗
42. 10.1016/j.isci.2023.10732310.1016/j.isci.2023.107323 ↗
43. 10.1128/jvi.76.5.2518‐2528.200210.1128/jvi.76.5.2518‐2528.2002 ↗
44. 10.3390/v1111099910.3390/v11110999 ↗
45. 10.1089/vim.2014.006810.1089/vim.2014.0068 ↗
46. 10.1016/j.bpj.2021.01.02510.1016/j.bpj.2021.01.025 ↗
47. 10.21769/BioProtoc.264610.21769/BioProtoc.2646 ↗
48. 10.1002/path.445610.1002/path.4456 ↗
49. 10.1002/jgm.28110.1002/jgm.281 ↗
50. 10.1089/1043034995001773410.1089/10430349950017734 ↗
51. 10.1038/7865410.1038/78654 ↗
52. 10.1001/jama.287.18.239110.1001/jama.287.18.2391 ↗
53. 10.1016/j.heliyon.2023.e1805910.1016/j.heliyon.2023.e18059 ↗
54. 10.3390/v1401014210.3390/v14010142 ↗
55. 10.3389/fmicb.2017.0157110.3389/fmicb.2017.01571 ↗
56. 10.1371/journal.ppat.100993710.1371/journal.ppat.1009937 ↗
57. 10.1371/journal.ppat.100450910.1371/journal.ppat.1004509 ↗
58. 10.1038/s42003‐022‐03767‐110.1038/s42003‐022‐03767‐1 ↗
59. 10.1016/j.tibs.2021.11.00310.1016/j.tibs.2021.11.003 ↗
60. 10.1111/tan.1289810.1111/tan.12898 ↗
61. 10.3389/fmicb.2013.0026710.3389/fmicb.2013.00267 ↗
62. 10.1038/s41467‐023‐43206‐110.1038/s41467‐023‐43206‐1 ↗
63. 10.1074/jbc.RA118.00656310.1074/jbc.RA118.006563 ↗
64. 10.1080/15548627.2025.249287710.1080/15548627.2025.2492877 ↗
65. 10.1016/j.antiviral.2021.10514110.1016/j.antiviral.2021.105141 ↗
66. 10.1128/JVI.79.2.918‐926.200510.1128/JVI.79.2.918‐926.2005 ↗
67. 10.1038/s41467‐025‐63295‐410.1038/s41467‐025‐63295‐4 ↗